Gagan Sharma designated Senior Management Personnel as President – Specialty Business
Evonile Pharma (formerly Novartis India) has designated Mr. Gagan Sharma as a Senior Management Personnel with effect from October 26, 2026.
By ScoutQuest · · 1 min read
- Effective Date
- October 26, 2026
- Designation
- Senior Management Personnel
- Role
- President – Specialty Business
What the company informed the exchanges
Evonile Pharma Limited, formerly Novartis India Limited, has told the exchanges that Mr. Gagan Sharma, President – Specialty Business, is being designated as a Senior Management Personnel with effect from October 26, 2026. The reason recorded for the change is "Appointment".
Who is Mr. Gagan Sharma:
- The update describes him as a senior pharmaceutical leader with over 30 years of experience across diverse commercial functions.
- Most recently, he served as Therapy Area Head – Gene Therapy, Immunology and In-Market Brands at Novartis Healthcare Private Limited, where he was a member of the India Leadership Team.
- The update credits him with driving strategic growth, leading business transformation, building sustainable competitive advantage, developing future leaders and accelerating brand performance through innovative commercial models and integrated omnichannel strategies.
- His stated areas of expertise include global product launches, portfolio management, brand revitalisation, market shaping and commercial excellence across specialty and established brands.
What kind of announcement this is
- This is a senior management designation, not a board appointment. The update states that disclosure of directorship between Directors is "Not applicable".
- No financial terms, remuneration details or share-related elements are part of this intimation.
How to read it
A designation of a business head as Senior Management Personnel tells investors who is formally responsible for a key part of the company's operations and brings that role into the disclosed senior management fold. The update is a people-and-role update; the hard financials of the company are not part of it.
Also from Evonile Pharma
Evonile Pharma reports first results after change of control
3 Nov 2026
Evonile Pharma Q2 and H1 FY27 results update: Q2 revenue down 38% YoY after business-model change
3 Nov 2026
Board approves unaudited results for September 2026 quarter; auditors' limited review unmodified
3 Nov 2026
More numbers
- Experience of Mr. Gagan Sharmaover 30 years
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.